The Evolving Landscape of Behavioral Health Transactions: Insights from Industry Professionals
AGG Talks: Cross-Border Business Podcast - Episode 19: The Rise of Korean Investment in the Southeast U.S.
The Standard Formula Podcast | Insurers in Difficulty: Staying Compliant Under Solvency II
Navigating Facility Relocation: Legal and Practical Considerations — The Consumer Finance Podcast
Public M&A Day in Frankfurt
JONES DAY TALKS®: Corporate Venture Capital: Market Overview, Trends in Deal Terms, and Special Considerations
La Financiación de Proyectos de Infraestructura
PLI's inSecurities Podcast - Commissioner Uyeda on “the Perils of Regulation by Theory and Hypothesis”
The Standard Formula Podcast | Back to Basics: Exploring the Many Facets of the Solvency II Regime
JONES DAY TALKS®: Preparing for FRTB: What Banks Should Know
Global Capital Markets Update with Kroll
Exit Strategies for GOVCONs with Set Aside Contracts: 2021 Insights and Lessons Learned from Business Owners and Advisors
Venture Capital: Global State of the Market
Cameras Roll on Spicer and Miller Discussing 2016 Entertainment Trends and Looking Forward to 2017
Debt Financing Trends – Joe Price, Member, Corporate & Securities Practice
Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more
Digital health is showing signs of life despite financial markets that seem determined to bring some of 2023’s volatility into the new year. Stocks are up and down, and bond yields are climbing. Inflation is proving stubborn,...more
Please join McDermott for our highly anticipated Life Sciences Dealmaking Symposium! Now in its 12th year, the Symposium offers a unique platform for education, insight sharing, purposeful networking and strategic...more
In this issue of the 2022 Technology and Life Sciences IPO Report, we present analysis related to 10 initial public offerings (IPOs), valued at over $75 million, completed by U.S.-based technology and life sciences companies...more
As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next? Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more
The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more
This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include: Investment...more
It is now a year since the WHO declared an International Public Health Emergency after the first international case of a novel coronavirus infection was identified outside of China. We remain right in the middle of spiralling...more
Despite political and economic uncertainties, markets and deal activity were resilient in 2019, and strong fundamentals remain in place heading into 2020. Companies continue to face a challenging litigation and enforcement...more